Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05067127
Study type Interventional
Source Apellis Pharmaceuticals, Inc.
Contact Apellis Clinical Trial Information Line
Phone 617-977-5700
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date October 2021
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Withdrawn NCT02302755 - TP10 Use in Patients With C3 Glomerulopathy (C3G) Phase 1
Active, not recruiting NCT03459443 - A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Phase 2
Completed NCT03369236 - A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G) Phase 2
Completed NCT01221181 - Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy Phase 1
Active, not recruiting NCT03453619 - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Phase 2
Terminated NCT01791686 - Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Phase 1
Recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Active, not recruiting NCT03723512 - Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study N/A
Withdrawn NCT00583427 - Sulodexide Treatment in Patients With Dense Deposit Disease Phase 1
Completed NCT03124368 - A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Phase 2